Janux Therapeutics, Inc. cash flow to debt ratio of -371.45% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Janux Therapeutics, Inc.'s free cash flow has decreased 88.53% from $-44.17M last year to $-83.28M, signaling decreasing performance

Janux Therapeutics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Janux Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.02 today, signaling strengthened financials

Janux Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Janux Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Janux Therapeutics, Inc.'s profit margin has increased (-18.72%) in the last year from -651.62% to -529.67%, signaling increasing performance

Janux Therapeutics, Inc.'s short-term assets of $975.89M exceed its short-term liabilities of $25.00M

Janux Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Janux Therapeutics, Inc.'s return on equity of -11.85%, is lower than 15.00%, indicating bad performance

Janux Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Janux Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Janux Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Janux Therapeutics, Inc. has negative free cash flow, indicating cash burn

Janux Therapeutics, Inc.'s yearly earnings has decreased 64.69% since last year from $-68.99M to $-113.62M, signaling decreasing performance

Janux Therapeutics, Inc.'s yearly revenue has decreased -5.55% since last year from $10.59M to $10.00M, signaling decreasing performance

ROIC -16.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Janux Therapeutics, Inc.'s 3-year revenue CAGR of 5.11% is positive, indicating growing revenue over the past 3 years

Janux Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Janux Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Janux Therapeutics, Inc. has insufficient data to evaluate this check.

Janux Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Janux Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Janux Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Janux Therapeutics, Inc. has insufficient data to evaluate this check.

Janux Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Janux Therapeutics, Inc. has a price-to-book ratio of 1.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Janux Therapeutics, Inc. has a price-to-sales ratio of 45.75x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue